This FTSE small cap is up over 800% in 2020. Here’s what I’d do now

This Fool looks at a FTSE AIM small-cap company whose share price has increased massively as it works on a coronavirus treatment.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE and global markets have crashed in the past three months. This is a result of the coronavirus pandemic and related economic shutdown. 

Biotech and healthcare companies are now in a race to try to create a vaccine. As well as a vaccine, some companies are creating other tools in response to the virus such as apps for testing information.

It’s not just the major pharmaceutical companies that are working hard to create a vaccine. There are other smaller companies you may not have heard of who are also in the fight. One such company is Synairgen (LSE:SNG). 

FTSE AIM resident

Synairgen is a respiratory drug discovery and development company founded by three University of Southampton professors. Its primary focus is on lung viral defence and its current product, known as SNG001, may have potential coronavirus applications.

Synairgen has been on the FTSE AIM index for nearly 15 years so it is not a company created in direct response to the pandemic. It has access to the scientific and clinical research facilities of Southampton General Hospital. 

SNG001 is wholly owned by Synairgen and is based on existing intravenous antiviral treatment. A potential new inhaler version could deliver it straight to the lungs. This is where damage is done by the coronavirus. Synairgen could benefit from having a tried and tested drug, in comparison to other companies that are starting from scratch. 

Recent news and performance

At the end of March, Synairgen announced its plans for testing SNG001. Its CEO commented, “A successful outcome from this trial in Covid-19 patients would be a major breakthrough in the fight against this coronavirus pandemic.” 

Since the turn of the year, Synairgen’s share price has increased over 800%. This makes it one of the best performing stocks in the UK in 2020. It is easy to understand why its share price has risen rapidly with the treatment it could potentially create. On 2 January, its per share price was 5.87p. At the time of writing it is closer to 55p. 

The company has been profitable in recent years although most of the money it makes is channelled back into research and development. This has resulted in some years showing a loss. After the trial announcement, Synairgen announced £14m in new funding based on offering new ordinary shares. It has confirmed this money would be used to fund the trials announced a week earlier. 

Verdict

I would not put all my eggs into one basket when it comes to coronavirus vaccine stocks. I would especially not put them all into a small cap company. However, I feel Synairgen is the type of low-price small cap that could be worth a gamble. I don’t see an issue in investing a small amount of money.

I would not be able to tell you how many companies there are out there trying to create vaccines and treatments. But I do know for certain that not all will succeed. So, as long as you understand that there are risks and you’re prepared for a loss, what is the harm in trying a small cap? Of course, you could play it safer and look to a bigger FTSE name such as GlaxoSmithKline.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jabran Khan has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »